Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TK1 | P04183 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137986 | 0.92 | MAPK1 (0.37) | TK2HPGDRAB9ATK1MAPK1 | |
| SCHEMBL21525037 | 0.89 | HPGD (0.36) | TK2HPGDPKMRAB9ATK1 | |
| SCHEMBL21525073 | 0.87 | LMNA (0.35) | TK2HPGDPKMRAB9ATK1 | |
| SCHEMBL4418604 | 0.87 | TK1 (0.35) | TK2HPGDCA1CA2CA12 | |
| SCHEMBL4414797 | 0.84 | TK1 (0.37) | TK2HPGDCA1CA2CA12 | |
| SCHEMBL4425730 | 0.83 | ADORA3 (0.39) | TK2CA1CA2CA12CA9 | |
| SCHEMBL4417043 | 0.80 | MEN1 (0.38) | TK2HPGDCA1CA2CA12 | |
| SCHEMBL15225666 | 0.80 | HPGD (0.36) | TK2HPGDPKMRAB9ATK1 | |
| SCHEMBL4414566 | 0.79 | CA12 (0.38) | TK2HPGDCA1CA2CA12 | |
| SCHEMBL4415959 | 0.79 | DDX3X (0.34) | TK2HPGDCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2174936-B1 | PNA monomer and precursor | PANAGENE INC (KR) | 2013-09-04 | — | — | EP | disclosed |
| EP-2174936-A1 | PNA monomer and precursor | Panagene, Inc. (KR) | 2010-04-14 | — | — | EP | disclosed |
| EP-1501812-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-12-30 | — | — | EP | disclosed |
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7371859-B2 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-7145006-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-12-05 | — | — | US | disclosed |
| US-7125994-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-10-24 | — | — | US | disclosed |
| US-20060030709-A1 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2006-02-09 | — | — | US | disclosed |
| US-20060008835-A1 | PNA monomer and precursor | KIM SUNG K | 2006-01-12 | — | — | US | disclosed |
| US-20060003374-A1 | Method of making PNA oligomers | KIM SUNG K | 2006-01-05 | — | — | US | disclosed |
| US-20050283005-A1 | PNA monomer and precursor | KIM SUNG K | 2005-12-22 | — | — | US | disclosed |
| US-6969766-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-29 | — | — | US | disclosed |
| US-20050250785-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20050250786-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20030225252-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030709-A1 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | RNGTT, POLL, RNMT | TK2 1134/4885HPGD 4004/4885CA1 2957/4885 |
| US-20050283005-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | TK2 1203/4885HPGD 3713/4885CA1 2552/4885 |
| US-20050250785-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | TK2 1203/4885HPGD 3713/4885CA1 2552/4885 |
| US-20030225252-A1 | PNA monomer and precursor | PNISR, RNGTT, NCL | TK2 1306/4885HPGD 3726/4885CA1 2094/4885 |
| US-20060008835-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | TK2 1203/4885HPGD 3713/4885CA1 2552/4885 |
| US-20050250786-A1 | PNA monomer and precursor | PNISR, RNGTT, NPR1 | TK2 1068/4885HPGD 2418/4885CA1 2968/4885 |
| US-20060003374-A1 | Method of making PNA oligomers | RNGTT, POLL, PNISR | TK2 1119/4885HPGD 3841/4885CA1 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.